Cyclopharm
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 28 Sept 2026
- Reported shorts
- 343
- Shares on issue
- 125.734M
Cyclopharm (CYC) Short Interest
Cyclopharm (ASX:CYC) had 0.00% of shares reported as short positions as of 28 Sept 2026, representing 343 shares. Cyclopharm operates in the Health Care Equipment & Services industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Cyclopharm
Cyclopharm is a global radiopharmaceutical company focused on lung imaging solutions. Their flagship product, Technegas, is used for pulmonary embolism diagnosis and other lung conditions. The company aims to advance nuclear pulmonology imaging through innovation and a commitment to superior patient care.
Company profile →Cyclopharm (ASX:CYC) has 0.00% of its shares on issue reported as short positions as of 28 Sept 2026, or about 343 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.19% in August 2025. CYC is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads CYC today
- Zanger BreakoutWatchScore 14rank 1545 of 1931
- CAN SLIMNot a candidate
- Minervini Trend TemplateNot a candidate
- Crowded-Short BreakoutNot a candidate
- Quality compoundersWatchScore 15rank 966 of 1677
Prices to 13 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
CYC fundamentals
In the half year to 30 Jun 2026, Cyclopharm (ASX:CYC) recorded a net loss after tax of A$8.8M. Year-on-year growth: revenue −39.5% (FY). Net margin −103.6%, return on equity −52.5% (TTM). Figures are in AUD, the company's reporting currency; source: Company filing (extracted) and Yahoo Finance, as at 13 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest CYC news
All news- Cyclopharm (ASX:CYC): US Technegas Growth Meets a Tougher Rollout Timetable - Kalkine
googlenews · 9 Oct 2026
- Does China Endorsement Lift Cyclopharm's Outlook (ASX:CYC)?
kalkine · 8 Oct 2026
- Cyclopharm’s Technegas Named as Preferred Ventilation Agent for Lung Imaging in China
smallcaps · 6 Oct 2026
Company details
website
address
More Health Care Equipment & Services Stocks
Other shorted stocks in this sector
Be the first to discuss CYC
Start a research thread or post the first pulse update